Thank you for joining us in Chicago. We hope you were able to see that OPDIVO® (nivolumab) + YERVOY® (ipilimumab) and 2 cycles of chemotherapy* now has 5 years of follow-up data for PD-L1 <1% r/m NSCLC. Explore the data HERE and see why it may be time to reevaluate your current treatment approach.

INDICATION

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

Visit the website to learn more.